FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jacqueline Greer

Research Profile

Disorders

Procedures

Concepts & Ideas

Chemicals & Drugs

Anatomy

Co-author Network

Publications

TOP 3
Michael W Evans; Ivana Gojo; Jacqueline Greer; Judith E Karp; Mark Levis; Anthony D Sung; Michael L Tidwell; Maria R Baer
Risk assessment in human immunodeficiency virus-associated acute myeloid leukemia.
Judith E Karp; Francis Giles; Ivana Gojo; Lawrence Morris; Jacqueline Greer; Bonny Johnson; Mya Thein; Mario Sznol; Jennifer Low
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
Judith E Karp; Rebecca M Ricklis; Kumudha Balakrishnan; Janet Briel; Jacqueline Greer; Steven D Gore; B Douglas Smith; A MICHAEL MCDEVITT; Hetty Carraway; Mark Levis; Varsha Gandhi
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jacqueline Greer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Michael W Evans; Ivana Gojo; Jacqueline Greer; Judith E Karp; Mark Levis; Anthony D Sung; Michael L Tidwell; Maria R Baer
Risk assessment in human immunodeficiency virus-associated acute myeloid leukemia.
Leukemia & lymphoma 2012;53(4):660-4.
2008: Judith E Karp; Francis Giles; Ivana Gojo; Lawrence Morris; Jacqueline Greer; Bonny Johnson; Mya Thein; Mario Sznol; Jennifer Low
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
Leukemia research 2008;32(1):71-7.
2007: Judith E Karp; Rebecca M Ricklis; Kumudha Balakrishnan; Janet Briel; Jacqueline Greer; Steven D Gore; B Douglas Smith; A MICHAEL MCDEVITT; Hetty Carraway; Mark Levis; Varsha Gandhi
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.
Blood 2007;110(6):1762-9.
2007: Ivana Gojo; Michael L Tidwell; Jacqueline Greer; Naoko Takebe; Karen Seiter; Mary F Pochron; Bonny Johnson; Mario Sznol; Judith E Karp
Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies.
Leukemia research 2007;31(9):1165-73.
2007: Judith E Karp; B Douglas Smith; Mark Levis; Steven D Gore; Jacqueline Greer; Catherine Hattenburg; Janet Briel; Richard J Jones; John J Wright; A Dimitrios Colevas
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 1):4467-73.
2007: Ivana Gojo; Anchalee Jiemjit; Jane Trepel; Alex Sparreboom; William D Figg; Sandra Rollins; Michael L Tidwell; Jacqueline Greer; Eun Joo Chung; Min-Jung Lee; Steven D Gore; Edward A Sausville; James Zwiebel; Judith E Karp
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.
Blood 2007;109(7):2781-90.
2007: Jeffrey E Lancet; Ivana Gojo; Jason Gotlib; Eric J Feldman; Jacqueline Greer; Jane L Liesveld; Laura M Bruzek; Lawrence Morris; Youn Park; Alex A. Adjei; Scott H Kaufmann; Elizabeth Garrett-Mayer; Peter L Greenberg; John J Wright; Judith E Karp
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.
Blood 2007;109(4):1387-94.
2005: Judith E Karp; Antonino Passaniti; Ivana Gojo; Scott Kaufmann; Keith C Bible; Tushar S Garimella; Jacqueline Greer; Janet Briel; B Douglas Smith; Steven D Gore; Michael L Tidwell; Douglas Ross; John J Wright; A Dimitrios Colevas; Kenneth S. Bauer
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(23):8403-12.
2005: Scott H Kaufmann; Judith E Karp; Louis Letendre; Timothy J Kottke; Stephanie L Safgren; Jacqueline Greer; Ivana Gojo; Pamela J Atherton; Phyllis A Svingen; David Loegering; Mark R Litzow; Jeff A Sloan; Joel M Reid; Matthew M Ames; Alex A. Adjei; Charles Erlichman
Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(18):6641-9.
2004: Judith E Karp; Ivana Gojo; Roberto Pili; Christopher D Gocke; Jacqueline Greer; Chuanfa Guo; Zheng (David) Qian; Lawrence Morris; Michael L Tidwell; Helen Chen; James Zwiebel
Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(11):3577-85.
2003: Judith E Karp; Douglas Ross; Weidong Yang; Michael L Tidwell; Yuetong Wei; Jacqueline Greer; Dean L Mann; Takeo Nakanishi; John J Wright; A Dimitrios Colevas
Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):307-15.